Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Sonosynthesis of new functionalized optically active triazines via double Mannich reaction: antibacterial potential and in silico docking study

Hajar A. Alia, Mohamed M. Hammoudaab, Mohamed A. Ismaila and Eslam A. Ghaith*ac
aChemistry Department, Faculty of Science, Mansoura University, El-Gomhoria Street, Mansoura 35516, Egypt. E-mail: abdelghaffar@mans.edu.eg; Tel: +2010244410784
bDepartment of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
cChemistry Department, Faculty of Science, New Mansoura University, New Mansoura City, Egypt

Received 21st February 2025 , Accepted 16th May 2025

First published on 4th June 2025


Abstract

In this study, we employed both conventional and ultrasound irradiation approaches to fabricate a library of ten new triazine hybrids by the divergent double-Mannich reaction. The titled compounds were characterized by extensive spectral analyses, including IR, MS, 1D NMR (1H, 13C, 15N, 19F), and 2D NMR (DEPT135, HSQC). Additionally, their antibacterial activity against a spectrum of bacterial strains, encompassing two Gram-positive and two Gram-negative bacteria, was assessed. Notably, compound 9 emerged as the most potent antibacterial agent with an inhibition zone of 39 mm against Bacillus subtilis, 50 mm against Staphylococcus epidermidis, 41 mm against Enterobacter cloacae, and 40 mm against Escherichia coli. Moreover, molecular docking simulation demonstrated the responsible binding affinity of the synthesized scaffolds with target proteins (PDB: 1OF0, 8P20, 1KQB, 1KZN). Likewise, structure–activity relationship (SAR) studies of the newly synthesized triazine derivatives demonstrated that substituent identity significantly impacts antibacterial activity. Notably, compound 9, bearing chloro and fluoro atoms, exhibited the highest antibacterial activity among all tested derivatives. Furthermore, optical activity measurements were performed through a polarimeter to confirm the tetrahedral stereocenter of nitrogenous scaffolds.


1 Introduction

Recently, the incidence of microbial infections and the emergence of resistance to current drugs have posed significant threats to human health, as one of the leading causes of death around the world.1–4 The etiology of this pathological phenomenon poses a formidable challenge in clinical studies, which can be attributed to the potential impacts of microbial infections on mortality and morbidity, causing serious fear and inconvenience. On the other hand, many reports expect that fatalities due to infections from multi-drug resistant (MDR) bacteria will exceed those from cancer by 2050 due to the long turnaround time and the limited efficacy of existing antibiotics against MDR.5–8 If no restricted measures are implemented, the annual death toll is projected to reach 10 million by 2050.9 In the same context, various spanning families of MDR pathogens were listed in the WHO's Bacterial Priority Pathogens List (WHO BPPL) for the year 2024, due to their concerns about treatability and transmissibility.10 As a result, it is imperative to synthesize and develop new antibacterial agents to overcome antibacterial resistance mechanisms that have eluded contemporary therapies due to their accelerated activities.11–14

On the other hand, nitrogenous heterocyclic scaffolds are the basic moieties in various bioactive natural products and approved purchasable antibiotics such as penicillin, levofloxacin, and cefalexin. According to recent reports, approximately 60–75% of small molecules drugs approved by FDA are nitrogenous heterocyclic systems2,15 Among these scaffolds are triazine and its diverse derivatives, as they have a track record of medicinal applications such as antibacterial,16 antimicrobial,17 antiviral,18–20 antiulcer,17 anti-inflammatory,21 anticonvulsant,22 pyruvate dehydrogenase kinase inhibitors,23 and herbicidal agents.24–26 Additionally, some triazine molecules are omnipresent in medicinally active compounds and marketed drugs such as oteracil,27 tretamine,28 lamotrigine,29 and tirapazamine (Fig. 1).30


image file: d5ra01283j-f1.tif
Fig. 1 Some marketed drugs containing triazine molecules.

Based on these considerations and aiming at combating drug-resistant infections, we synthesized new triazines as central cores linked to various bioactive hybrids. Also, these synthesized hybrids were evaluated as antibacterial agents against four bacterial strains. Eventually, the results were analyzed and validated in light of the molecular docking, confirming an extensive approach to the experimental and theoretical results.

A rational design was employed to investigate and develop new antibacterial agents, leveraging established evidence that scaffolds such as azabiphenyl,31–33 difluoro-chlorophenyl rings,34 and both 1,2,4- and 1,3,5-triazine hybrids35,36 could exhibit potent in vitro antibacterial activities. In this study, our objective is to synthesize a series of lead triazine scaffolds incorporating fluoro-chlorophenyl, azabiphenyl, benzidine, diphenylamine, tryptamine, and antipyrine as bioactive moieties, and subsequently evaluate their antibacterial activities (Fig. 2).


image file: d5ra01283j-f2.tif
Fig. 2 Rational design of triazine compounds for antibacterial activities.

2 Results & discussion

Herein, an optimized approach was achieved to design and synthesize novel triazine derivatives incorporating numerous aliphatic, aromatic, and heteroaromatic entities through a straightforward multicomponent Mannich reaction. As the key starting material 1, was synthesized according to previously reported methodology37 via diazotization reaction of aniline with NaNO2 and HCl at 0 °C, then coupling the diazonium salt with ethyl acetoacetate afforded (phenylhydrazineylidene)propan-2-one 1 (Scheme 1). Scaffold 1 was elucidated through the 1HNMR spectrum that revealed the presence of NH at δ = 11.33 ppm, and the 13CNMR of the carbonyl group of 1 appeared at δ = 196.84 ppm.
image file: d5ra01283j-s1.tif
Scheme 1 Synthesis of new 1,2,4-triazine derivatives.

Multicomponent reactions (MCRs) of 1 with dodecyl amine as aliphatic amine and formalin (CH2O) in refluxing EtOH on a water bath via double Mannich reaction afforded 1-(4-dodecyl-2-phenyl-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one 2 (Scheme 1). The structure of skeleton 2 was confirmed through its 1HNMR spectrum displaying three singlet signals at δ = 2.34, 3.49, 4.56 ppm for the methyl of the acetyl group and two deshielded methylene groups of the triazine moiety. Besides, two triplet signals at δ = 0.86 and 2.41 ppm correspond to dodecyl protons. Also, the 13C NMR spectrum of skeleton 2 exhibited characteristic dodecyl aliphatic carbon signals at δ = 14.44 to 31.77 and 53.33 ppm, in addition to the aliphatic carbons of triazine moiety at δ 45.65 and 64.60 ppm. The mass spectrometry of compound 2 displayed a molecular ion peak (m/z) = 371.14 attributed to C23H37N3O. Analogous to compound 2, treatment of 1 with tryptamine in EtOH yielded the crude product of compound 3 instead of the desired product 4 (Scheme 1). The residue was purified using preparative silica gel chromatography to yield a sol product identified as ((hydroxymethyl)-indol-tetrahydro-triazin-6-yl)ethanone 3. The structure of constitution 3 seemed to be consistent with its spectral data as its 1HNMR spectrum exhibited a singlet signal associated with the hydroxyl group at δ = 11.61 ppm, beside the olefinic proton of the indole ring at δ = 10.75 ppm. Further, 13C NMR highlighted the formation of compound 3 with significant carbons resonating at δ 24.51, 49.91, 50.34, 50.47, 79.58 ppm corresponding to five methylene carbons.

It was noteworthy that bis-triazine 6 was synthesized, instead of the anticipated diphenylboraneyl ethoxy triazine 7. Initially, the reaction was carried out with the detachment of 2-aminoethyl diphenylborinate (5), followed by dimerization to afford 2,2′-oxybis(ethan-1-amine) (6A).38–40 Ultimately, Mannich product 6 was obtained by aminomethylation of oxybis(ethanamine) 6A with 1 and CH2O. The resulting product 6 was separated chromatography and characterized by 1HNMR spectrum with a distinctive triplet signal at δ 2.54 due to aza methylene protons (–NCH2C–), in addition to four multiplet signals at δ 3.53–3.56, 4.61–4.65, 7.03–7.07, and 7.35–7.40 corresponding to oxy ethylene (–OCH2CH2N–), methylene-H's of triazine ring, the other singles were related to aromatic protons, respectively. Meanwhile, 13CNMR spectrum of 6 showed 11 signals including; the methyl of acetyl group reverberated at δ 23.84 (2C), the methylene carbons bonded to nitrogen and oxygen atoms appeared at δ 55.96 (2C), 59.83 (2C), respectively and the methylene carbon of triazine ring showed at δ 46.44 (2C) and 65.11 (2C). Moreover, the quaternary carbons of the triazine ring appeared at δ 145.26 (2C), and the carbons of the carbonyl group resonated at 196.01 (2C). In contrast, all these quaternary carbons disappeared in DEPT (135) as shown in the ESI file. On top of that, six nitrogen atoms were clearly evidenced by 15N NMR spectroscopy and revealed signals at −6.98, 199.98, and 406.95 ppm (Fig. 3).


image file: d5ra01283j-f3.tif
Fig. 3 15N-NMR spectrum of compound 6.

In general, the preparation of triazine derivatives may be rationalized based on a depicted mechanism (Scheme 2) involved via bis-Mannich reaction ongoing with the condensation of amine with formalin to produce an intermediate methylol derivative 2A, followed by removal of the two hydroxyl groups to afford carbonium ion 2B, RN(CH2+)2, in addition, elimination of two acidic protons from 1 yielded the carbanion intermediate 1A. Finally, a carbanion 1A reacted with carbonium ions 2B to form triazine derivatives 2.41,42


image file: d5ra01283j-s2.tif
Scheme 2 A postulated mechanism for the formation of triazine derivatives.

Similarly, refluxing of 1 with 4-bromoaniline or 2-chloro-3-fluoroaniline and CH2O in EtOH furnished bromophenyl-2-phenyl-tetrahydro-triazinethanone 8 and (chloro-fluorophenyl-2-phenyl-tetrahydro-triazinyl)ethanone 9, respectively (Scheme 3). The structures of compounds 8 and 9 were supported by analytical and spectral data. As the mass spectra of constitutions 8 and 9 showed molecular ion peaks (m/z) at 358.41 and 331.54, respectively. Also, 13C NMR of skeleton 8 revealed 13 carbon signals corresponding to the elucidated constitution. However, the presence of a fluorine atom in compound 9 will cause signal splitting in 13C NMR due to a phenomenon known as the 19F–13C coupling so 13C analysis cannot be performed.43,44 To provide additional confirmation of the formation of compound 9, 19F NMR was conducted, revealing a singlet signal at −δ 126.87 ppm related to one fluorine atom.


image file: d5ra01283j-s3.tif
Scheme 3 Treatment of 1 with substituted aniline.

Encouraged by the aforementioned results, we expanded our research to include aromatic amines with different spacers, such as imino, carbonyl, and azo groups. Mannich reaction of 1 with N-phenyl-p-phenylenediamine or 4-aminobenzophenone and CH2O afforded ((4-(phenylamino)phenyl)tetrahydrotriazin)ethanone 10, and (4-benzoylphenyl)-2-(phenyl-tetrahydro-triazin-6-yl)ethanone 11, respectively, as illustrated in (Scheme 4). The IR spectrum of compound 10 displayed a characteristic band at 3353 cm−1, corresponding to the NH group. Additional supporting evidence for the skeleton 10 was provided by 1HNMR, which displayed four singlet signals at δ = 7.92, 5.20, 4.18, and 2.36 ppm related to the NH group, two methylene groups, and the CH3CO– group, respectively. In addition, its mass spectrum showed m/z at 370.41, which was in accordance with its molecular weight (see experimental part). The IR spectrum of compound 11 showed a prominent absorption band at 1723 and 1669 for (2C[double bond, length as m-dash]O). Furthermore, its 1H NMR exhibited three singlet signals for the methyl of acetyl group and two methylene-H's of the triazine moiety at δ 2.39, 4.39, and 5.41 ppm. Meanwhile, the two carbonyl groups emerged in the 13C analysis at δ 194.55 and 195.64 ppm, yet concurrently, they were substantiated to have dissipated in the DEPT 135 spectrum.


image file: d5ra01283j-s4.tif
Scheme 4 Synthesis of polyfunctionalized triazines with different spacers.

In this line, we aimed to synthesize compound 13 via Mannich reaction, while ((4-nitrophenyl)diazenyl)phenyl-1-(phenylhydrazineylidene)propanimine 12 was prepared through condensation of an amino group with the ketonic group of starting material 1. The IR spectrum of compound 12 revealed the presence of a new NH (PhNHN–) absorption band at 3272 cm−1. Whereby, 1HNMR of compound 12 confirmed the structure as revealing a singlet resonating signal at δ 13.33 ppm assigned to the NH group of 1. However, the protons of the two methylene groups were absent. Furthermore, its mass spectrum proved to possess m/z at 386.48.

The scope of the preparation of bis triazine derivatives was explored by refluxing 1 with benzidine and CH2O via bis double Mannich, yielding biphenyl-4,4′-bis(2-phenyl-tetrahydro-1,2,4-triazine-4,6-diyl)bis-ethan-1-one 14 as the anticipated product (Scheme 5). Once more, the constitution of compound 14 was based on mass spectrum, which showed a molecular ion peak at 556.87 (M+, 32.96%). On the other hand, 13C NMR displayed 14 carbon signals corresponding to C34H32N6O2.


image file: d5ra01283j-s5.tif
Scheme 5 Double Mannich reactions for the construction of triazines.

Likewise, the Mannich reaction of 1 with amino antipyrine and CH2O in refluxing EtOH afforded constitution 15 (Scheme 5). Notably, the DEPT 135 spectrum confirmed distinct signals according to the elucidated structure, as the spectrum exhibited the disappearance of signals associated with the quaternary carbon at δ 117.65, 135.40, 140.61, 144.76, and 151.81 ppm, as well as two carbonyl carbons at δ 162.56 and 195.64 ppm. Additionally, two methylene signals with negative phases were observed at 45.15 and 62.88 ppm, while characteristic positive signals were detected at δ 10.67, 24.10, and 36.57 ppm, corresponding to three methyl groups (Fig. 4).


image file: d5ra01283j-f4.tif
Fig. 4 DEPT (135) spectrum of compound 15.

The 1H, 13C NMR, and 2D NMR experiments, including the HSQC pulse sequence, provided valuable insights into the structural composition of compound 15. The acquired data revealed correlation plots, including the alpha methyl protons adjacent to the ketone group at δ 2.21(C6b: 10.67) as a singlet signal. Additionally, two methylene groups were observed at δ 3.95 (C5: 45.15), δ 4.85 (C3: 62.88), two methyl groups at δ 2.38 (C5′a: 24.10) and 3.00 (C1′a: 36.57) of the pyrazole ring Fig. 5.


image file: d5ra01283j-f5.tif
Fig. 5 Two-dimension HSQC spectrum of compound 15.

Multi-component reaction of 1 with 2-aminobenzonitrile or aminotriazole, or aminopyridine derivative with CH2O was expected to follow the same synthetic route to synthesize acetyl triazine derivatives 17a–c, but did not result in this formation, whereas, a deamination reaction, which was a major problem of Mannich reaction was occurred that might be due to the long time of the reaction or unwanted side reaction or a drastic reaction conditions which led to a methylene bisketone synthesis 16 (Scheme 6).45 Compound 16 was evidenced by 1HNMR which revealed the presence of characteristic signal related to two symmetrical NH groups at δ = 10.97 ppm, in addition to one methylene group at δ = 3.75 ppm. Consequently, 13C NMR displayed 8 signals, corresponding to 19 carbons, with a characteristic methylene carbon at δ = 19.82 ppm.


image file: d5ra01283j-s6.tif
Scheme 6 A deamination reaction mechanism of 1 for the synthesis of bis ketones.

Al-Mousawi et al.46 proposed a mechanistic pathway for the synthesis of bis(2-phenylhydrazineylidene)heptane-2,6-dione 16, starting with a methyolation reaction of one mole of 1 with one mole of CH2O in refluxing ethanol to afford a monomethylol intermediate 16A. On the other hand, the elimination of an acidic proton from another mole of 1 produced an anion intermediate 16C. Intermediate 16A was protonated to convert the bad leaving group (–OH) to the good leaving group (H2O) of intermediate 16B. Finally, bis-ketone product 16 was produced by condensing the anion intermediate 16C with intermediate 16B (Scheme 6).

Indeed, ultrasound is a highly green activation technique to meet the concept of sustainable chemistry in total organic synthesis,47 as it accelerates the reaction rate and allows significant results to be obtained in terms of atom economy through one-pot fashion, without purification of intermediates leading to lower time, costs and energy consumption over the conventional thermal methods.48–51 Therefore, we explored the obtained yields in the application of the Mannich reaction via both an ultrasound-assisted method and contrasting its efficacy with conventional synthetic techniques for the following compounds (Table 1).

Table 1 Time and yield of conventional method versus ultrasound-promoted synthesis of triazines
Compd US method Conv. method Comp. US method Conv. method
Time (min) Yield (%) Time (min) Yield (%) Time (min) Yield (%) Time (min) Yield (%)
2 45 66 45 47 10 45 66 45 42
60 76 60 50 60 75 60 50
75 84 75 52 75 79 75 56
90 90 90 56 90 86 90 59
105 93 105 64 105 95 105 67
120 96 120 67 120 98 120 78
3 45 71 45 22 11 45 69 45 37
60 78 60 43 60 71 60 44
75 81 75 49 75 77 75 49
90 84 90 55 90 79 90 51
105 88 105 67 105 89 105 67
120 90 120 78 120 94 120 72
6 45 40 45 20 12 45 52 45 35
60 45 60 23 60 67 60 41
75 51 75 28 75 71 75 55
90 54 90 33 90 74 90 58
105 58 105 36 105 89 105 62
120 62 120 42 120 97 120 70
8 45 80 45 35 14 45 45 45 31
60 85 60 50 60 54 60 37
75 90 75 55 75 60 75 44
90 92 90 60 90 64 90 58
105 95 105 75 105 79 105 61
120 97 120 80 120 85 120 68
9 45 31 45 21 15 45 71 45 22
60 34 60 28 60 78 60 43
75 38 75 31 75 85 75 49
90 45 90 35 90 89 90 55
105 49 105 41 105 91 105 67
120 54 120 48 120 95 120 78


Additionally, chirality is one of the fundamental characteristics of molecular asymmetry and plays an essential role in the manufacture of pharmaceuticals in governing molecular interactions and therapeutic efficacy.52 The majority of commercially available drugs are chiral,53 approximately 90% of chiral pharmaceuticals approved by the FDA exist as racemates-equimolar mixtures of two enantiomers. Although racemates share identical chemical composition and bonding patterns, their biological behavior diverges significantly in chiral environments. This dichotomy manifests in distinct pharmacological, toxicological, metabolic, and pharmacokinetic profiles.54–57 Whereby, chirality influences the metabolism of drugs by activating one enantiomer more than the other.58

Whereby, the synthesized constitutions possess nitrogenous stereocenters, optical rotations for the synthesized scaffold were assessed at a concentration (weight percent) = 0.0033%. Each solution was held in the glass cell with a length of 17.5 cm. The thin film was determined at a temperature of 21 °C and wavelength 589 nm on WXG-4. UV polarimeter, the specific rotation is represented by [α]λT = θ/CL, with being the rotational angle, C the concentration, and L the optical path length of the chiral liquid59–61 (Table 2).

Table 2 Specific rotation of triazine scaffolds containing chiral nitrogenous atoms
Compd Solvent θ C L [α]58921
1 DMF 5 0.0033 17.5 86.58
2 DMF 9 0.0033 17.5 155.84
3 DMF 7 0.0033 17.5 121.21
6 DMF 12 0.0033 17.5 207.79
8 DMF 5 0.0033 17.5 86.58
9 DMF 5 0.0033 17.5 86.58
10 DMF 12 0.0033 17.5 207.79
11 DMF 10 0.0033 17.5 173.16
12 DMF 16 0.0033 17.5 277.05
14 DMF 4 0.0033 17.5 69.26
15 DMF 6 0.0033 17.5 103.89


2.1 Antibacterial screening of the synthesized compounds

The bioactivity assessment revealed that some triazine derivatives exhibited considerable effectiveness against the tested bacteria, as demonstrated in Table 3 and Fig. S53.
Table 3 Presented the inhibition zone diameter (IZD, mm) of bacteria strains treated with triazine compounds compared to the control, azithromycin, after incubation for 72 h at 28 °C
Compound IZD
Bacteria strain B. subtilis S. epidermidis Entero. Cloacae E. coli
1 13 14
2 12
3 15 16 12
6
8 18
9 39 50 41 40
10 22 20 14 17
11 12 11
12 11 20
14 19 32 20 15
15 14 11 11 18
Positive control (azithromycin, 2 mg ml−1) 24 22 12 20
Negative control (DMSO)


2.2 Molecular docking studies

Additional enhancements can be implemented in in vitro research techniques to facilitate the rapid screening of enzyme inhibitors by applying molecular modeling. Consequently, integrating bioinformatics simulations with in vitro analyses is beneficial for assessing the biological activities of triazine compounds. Molecular docking provides valuable insights into the binding interactions between protein targets derived from bacterial strains and all the synthesized compounds,62,63 thereby enhancing our understanding of the underlying biological mechanisms. In this approach, we shed light on the notable inhibitory effects of triazines against the four bacterial strains through an in silico computational molecular docking study. The findings from this approach, illustrated in Tables 4–7, employed the compounds' screening of binding affinities with four bacterial protein receptors.
Table 4 Represented the molecular docking results involving bond length, amino acid interactions, and binding energy
Compd Binding affinity (kcal mol−1) H-bond interaction H-bond length in Å Hydrophobic as well as other interactions
1 −5.117 THR15 2.18 ILE173, PRO192, GLU61, ASP190
ASP187 2.84
2 −6.376 THR15 1.97 ILE12, LEU243, ASP187, VAL191, PRO192, GLU61, THR15
3 −9.089 THR15 1.80 ILE12, ASP187, PRO192, GLU61, THR15, TYR250
6 −7.203 THR15 2.34 ALA9, GLU188, ASP187, ASP190, ASP14, THR15, ILE173, PRO192, GLU61
ILE12 2.19
8 −7.555 THR15 2.02 THR15, ILE12, ASP187, PRO192, GLU61
9 −7.905 LEU184 2.44 ARG251, LYS180, GLU179, SER186, GLU61, ASP187, HIS175
10 −8.588 THR15 1.93 GLU61, PRO192, THR15, ILE12, ASP187, ASP190, LEU243
11 −8.985 THR415 2.79 VAL225, PRO226, ALA227, HIS497
HIS419 2.62
GLY417 2.91
12 −6.966 TYR381 2.72 SER216, GLY382, LEU219, PRO226, PRO212, PRO209
14 −9.084 ASP14, GLU61, ASP187, HIS175, LEU184, LYS180, ARG251, LYS63
15 −8.027 HIS497 2.79 THR260, CYS322, PRO226, ALA227, ARG416
HIS419 2.30
THR415 2.85


Table 5 Data extracted from the docking interactions of triazines against the 8P20 protein
Compd Binding affinity (kcal mol−1) H-bond interaction H-bond length in Å Hydrophobic as well as other interactions
1 −5.423 LYS74 2.70 LYS150, VAL152, TYR147, LYS148, ASP171, LYS74, LYS44
ALA45 2.07
2 −6.157 LYS44 2.79 LYS148, VAL152, LYS150, ASP171, ILE71, LEU51, LYS52, VAL55, LYS48
3 −8.203 ARG179 2.44 ALA45, TYR145, PHE43, LYS153, LEU163, GLU166, ILE181
6 −7.520 PHE43 3.22 TYR145, LYS153, ALA45, GLU155, GLU166, PHE43, ILE188
1.96
8 −7.259 TYR145 2.84 TYR145, PHE43, VAL152, TYR147, ALA45
9 −7.372 GLY16 2.35 GLU266, VAL250, GLU403, LEU407, GLY17, MET18
THR19 2.57
10 −8.020 LEU163, PHE43, TYR145, GLU155, ALA45, GLU129, ILE181, TYR147
11 −8.382 LYS233, ASN203 2.31, 2.57 LYS264, TYR268, PRO232, VAL204, ILE188, LYS 233
2.14
12 −8.195 LYS233, ASN203 2.41 VAL262, ALA261, LYS264, ASP267, TYR268, PRO232, VAL204
2.41
14 −9.797 TYR268 2.40 VAL204, PRO232, ILE188, LEU163, ILE181, LYS264, TYR268
ARG179 2.31
15 −9.561 SER408, LEU409 2.31 TYR382, ILE324, LEU407, SER325, GLU403, GLY406, GLY17, GLY16, THR20
2.47
ARG326 2.46


Table 6 The docking interactions and the binding energy of inhibitors with the 1KQB protein
Compd Binding affinity (kcal mol−1) H-bond interaction H-bond length in Å Hydrophobic as well as other interactions
1 −5.082 PHE48 2.92 LYS31, LEU34, PHE48, HIS47
HIS47 2.05
2 −5.815 LEU34, PHE48, HIS47, PHE183, TRP94, ALA93, TRP46
3 −7.519 LYS31, LEU34, PHE48, HIS47, VAL98, ARG97, TRP94
6 −6.469 GLN44 3.24 ASP105, LYS31, PHE48, LEU34
ARG97 3.07
TRP46 2.07
8 −6.714 TYR144, LYS141, LEU186, ALA140, GLN137, PHE167, ALA169
9 −6.880 LYS31 2.16 ILE49, PHE48, VAL50, LYS31
VAL50 3.36
10 −7.291 PHE167 2.25 ASP136, THR184, ALA140, GLN137, LEU186, ALA169, ALA170, ASP168
11 −7.079 TYR144, LEU186, GLN137, ALA140
12 −7.031 SER40 2.02 PRO163, GLU165, VAL187, LEU145, LYS141, GLN142, TYR144
TRP138 2.18
TYR144 3.38
14 −8.497 SER40, TRP138 2.05 LYS141, LEU145, TYR144, VAL147, PRO163, VAL187, TRP138
2.31
15 −8.107 GLN35 2.99 LEU34, LYS31, PHE48, ARG97, TRP94, TRP46
ARG97 2.24, 2.56


Table 7 Molecular docking interaction of target compounds against DNA gyrase protein 1KZN
Compd Binding affinity (kcal mol−1) H-bond interaction H-bond length in Å Hydrophobic as well as other interactions
1 −5.755 ASN46 2.10, 2.73, 2.53, 2.61 ILE78, ASP49, GLU50
2 −6.284 ALA86, ILE90, PRO79, ASN46, ALA47
3 −8.161 GLY77 2.65 ALA96, ILE90, VAL167, THR165, ALA47
GLU42 3.05
ASN46 2.67
6 −7.972 GLY117 1.94 PRO79, ILE78, ALA47, ASN46, ASP49, ASP45
HIS116 2.40
8 −7.345 ARG136 2.52, 2.74 ALA53, ASP49, ARG76, ILE78, VAL167, VAL120, ASN46
9 −7.544 ARG136 2.53 GLY77, GLU50, ALA47, ASN46, ILE78, ARG76, PRO79
ARG76 2.63
ASN46 2.55
10 −7.878 ARG76 2.19 PRO79, ILE90, ASN46, GLY77, VAL89, ILE78, ALA86
GLU50 3.37
11 −8.141 ARG76 2.89 ARG76, ALA53, LEU52, ILE78, ALA47, THR165, ASN46
12 −6.959 ASN46 2.83 ALA47, VAL43, THR165, VAL167, ASP73, ILE78, ILE90, PRO79, ALA86
14 −8.184 ARG76 2.38 VAL84, VAL89, ALA86, PRO79, ILE90, ASN46, ILE78
15 −8.236 ASN46 2.40 ILE78, ALA96, GLY119, GLU42, ILE90
HIS95 2.89


2.2.1 Docking and molecular protein interaction in Bacillus subtilis (PDB: ID 1OF0)64 with triazine compounds. Docking studies forecasted that compounds 3, 14, and 10 have the strongest binding affinity. Nonetheless, in vitro studies indicated that compound 9 stands out among all the synthesized compounds as it is a potent antibacterial against all tested bacteria. Moreover, compound 10 revealed astonishing inhibitory potential against B. subtilis, manifesting an inhibition zone diameter of 22 mm. The fluorine atom on the substituted phenyl ring of compound 9 with 1OF0 receptor forms a H-bond with key amino acid LEU184 (bond length: 2.44 Å) and hydrophobic interactions with SER186 (C–H bond), LYS180, GLU179 (two fluorine bonds), ARG251, HIS175 (π-cation), GLU61, ASP187 (π-anion) and HIS175 (π-alkyl) (Table 4, Fig. 6). Whereby, compound 10 forms one conventional H-bonds with 1OF0 protein with bond length 1.93 Å with amino acid THR15. Furthermore, eight hydrophobic bonds were noted with THR15, ILE12, LEU243, ASP190, ASP187, PRO192, and GLU61. One potential explanation for the discrepancy observed between theoretical predictions and experimental results is the limitations of docking calculations. These calculations employ mathematical models and algorithms to forecast how drugs interact with biological targets. However, they overlook critical factors such as how drugs are delivered, variations in experimental conditions, and the properties of the biological targets themselves.65 Meanwhile, the antibacterial assessment revealed that neither compounds 2 nor 6, 8, and 12 inhibited the growth of Bacillus subtilis. CotA laccase, a multicopper oxidase, in B. subtilis (PDB ID: 1OF0), engage in the formation and stabilization of the spore coat. This enzyme parades oxidoreductase activity and has been structurally characterized in the presence of ABTS, a standard non-catalytic substrate used to assess laccase function. CotA contributes to protect spores from environmental challenges such as ultraviolet radiation, oxidative stress, and enzymatic degradation during germination. Remarkably, triazine-based compounds have demonstrated inhibitory effects on B. subtilis growth by disrupting CotA laccase activity.66
image file: d5ra01283j-f6.tif
Fig. 6 Depictions of the 2D, 3D structures, and hydrophobic view of scaffolds 9 and 10 against 1OF0 protein.
2.2.2 Docking and molecular interaction of HA-MRSE [TarM(Se)] glycosylates RboP-WTA with glucose protein in Staphylococcus epidermidis (PDB: ID 8P20)67 with target compounds. The tested compounds presented variable activities in inhibiting S. epidermidis bacteria. Notably, compounds 9 and 14 demonstrated tremendous antibacterial effects, while compound 10 established good inhibition. The binding interaction of these compounds with S. epidermidis may induce structural changes in the enzyme, potentially leading to its inhibition.68 Conversely, it was found that compounds 2, 6, 8, and 11 exhibited no effectiveness against S. epidermidis, suggesting that these compounds might possess additional antibacterial mechanisms beyond merely inhibiting bacteria.69 The docking results revealed a favorable binding affinity, with the lowest binding energy recorded at −9.797, −9.561, and −8.382 kcal mol−1 for compounds 14, 15, and 11, respectively. The docking outcomes are rather aligned with the experimental. A fluorine atom can establish a halogen bond with specific amino acid residues in the target protein, specifically (GLU266). The carbonyl oxygen atom on the acetyl group of hybrid 9 created two H-bonds with the key amino acids GLY16 and THR19. The binding model of compound 9 was stabilized by hydrophobic interactions between the atoms of scaffold 9 and the residues MET18, GLY17, LEU407, GLU403, VAL250, and GLU266. On the other hand, compound 14 formed two H-bonds between the oxygen atoms on its acetyl groups with the active-site-facing amino acids TYR268 and ARG179. In addition, the four aromatic rings of compound 14 engaged in hydrophobic interactions with various residues, including LEU163, VAL204, LYS264 (π-alkyl), PRO232, VAL204 (alkyl interaction), ILE181, ILE188 (π-sigma), and TYR268 (π–π stacked) (Table 5, Fig. 7). The 8P20 protein, also known as Small Basic Protein (Sbp), is an 18-kDa component of S. epidermidis, primarily localizes at the boundary between the biofilm and the underlying surface. Sbp plays a key structural role in supporting biofilm matrix and persistence, improving stable bacterial attachment, and facilitating the development of complex, multilayered biofilm communities. Additionally, it engages in biofilm construction mechanisms dependent on both polysaccharide intercellular adhesin (PIA) and the accumulation-associated protein (Aap), displaying co-localization with Aap's Domain-B, which suggests its engrossment in promoting Aap-driven biofilm accumulation. Moreover, Sbp contributes to bacterial cell clustering and reinforces the biofilm's overall integrity by forming amyloid fibrils. Notably, triazine scaffolds have been shown to inhibit the function of the 8P20 protein, potentially disrupting biofilm integrity and surface colonization.70
image file: d5ra01283j-f7.tif
Fig. 7 Binding mode and visual interaction of synthesized compounds 9 and 14 with the binding active site of 8P20 protein.
2.2.3 Docking and molecular interaction of the nitro reductase enzyme in Enterobacter cloacae with tested compounds (PDB: ID 1KQB)71,72. Most of the tested compounds showed no activity toward Enterobacter cloacae except compounds 9, 10, 14 and 15. This is attributed to that the inactive compounds worked outside the cell membrane instead of inside it, leading them to bind to surface groups of the bacterial cells.68 As mentioned, compound 9 is an excellent paradigm against Enterobacter cloacae that showed an IZD of 41. It was revealed that the second most efficient compound in terms of antibacterial effect was compound 14. Compound 9 bonded with nitro reductase enzyme by two H-bonds with LYS31 and VAL50, and hydrophobic interactions with PHE48 (C–H Bond), ILE49 (π-sigma), VAL50, and LYS31 (alkyl, π-alkyl bond). Additionally, the conjugated system generated by the benzidine moiety as well as the substituted phenyl in compound 14 formed hydrophobic bonds with LYS141 (π-cation, π-sigma & alkyl), TYR144 (π–π, amide-π), TRP138, VAL147, PRO163, VAL187, and LEU145 (π-alkyl) that encourage electron delocalization, inducing its antibacterial activity. The individual significant H-bond interaction in compound 14 was formed between the oxygen of the carbonyl group and SER40, TRP138 over an intermolecular distance = 2.05 and 2.31 Å (Table 6, Fig. 8). The protein 1KQB from Enterobacter cloacae is a nitroreductase enzyme that belongs to a family of evolutionarily conserved proteins involved in the reduction of nitrogen-containing substrates. The oxidized form of nitroreductase has been elucidated through crystallographic studies in complex with benzoate, offering valuable insights into its catalytic mechanism and identifying potential sites for inhibitor binding. Triazine hybrids effectively inhibit the activity of nitroreductase, leading to the suppression of bacterial growth by targeting 1KQB.73
image file: d5ra01283j-f8.tif
Fig. 8 Molecular docking images of the inhibitors with the 1KQB protein.
2.2.4 Docking and molecular interaction of triazine scaffolds with DNA gyrase in Escherichia coli (PDB: ID 1KZN)74,75. The forecast by docking studies anticipated that compounds 15 > 14 > 3 demonstrate very high inhibitory binding affinities (Table 7). Nevertheless, compound 9 manifested the highest inhibition zone equal to 40 mm in the antibacterial assay, which is attributed to the dynamic interactions stemming from the presence of two halogens, F and Cl in compound 9, which generate a dipole moment because of their electronegativity, thereby enhancing the compound's binding affinity.76,77 For the bacterium E. Coli, the docking results illustrated in Fig. 9 showed that the interaction mechanism between scaffold 9 and the 1KZN protein relies mainly on three H-bonds with amino acids ARG136, ARG76, and ASN46 at distances of 2.53 Å, 2.63 Å and 2.55 Å, respectively, as well as, two F-bonds with GLY77 and GLU50 along with hydrophobic interactions. Whereas, compound 15 exhibited a binding energy of −8.236 kcal mol−1 due to its participation in H-bond interactions with ASN46 and HIS95. Additionally, it engages in π-sigma interactions with ILE90, two C–H bonds with GLY119, ALA96, π-anion with GLU42, and π-alkyl interactions with ILE78 (Table 7). The 1KZN protein in E. coli signifies the 24 kDa N-terminal domain of the DNA gyrase subunit B (GyrB). DNA gyrase is a type II topoisomerase that demonstrates a crucial role in introducing negative supercoils into double-stranded DNA, a process essential for DNA transcription, replication, and the maintenance of DNA topology in bacteria. The GyrB subunit is essential for catalyzing ATP hydrolysis, which provides the energy needed for the supercoiling activity of the enzyme. Triazine derivatives have been demonstrated to inhibit the action of 1KZN protein, resulting in inhibiting the growth of bacteria.78
image file: d5ra01283j-f9.tif
Fig. 9 Interaction modes of compounds 9 and 15 with E. coli protein (PDB: 1KZN).

2.3 SAR studies

Notably, triazine derivatives bearing electron-withdrawing atoms such as fluoro and chloro, on the aromatic ring, as exemplified by compound 9, significantly exhibit the highest potency with a minimum inhibitory concentration (MIC) of 1.87 mg mL−1.17b,79,80 This enhancement is attributed to the presence of strongly electronegative halogenated atoms,81 which can increase the electrophilicity of the triazine core,82 potentially improving interactions with bacterial targets and facilitating better cell penetration.83 In contrast, incorporating a bulky, electron-donating dodecyl group, as in compound 2, resulted in a detrimental effect on antibacterial activity against most bacterial strains. On the other hand, introducing a hydrogen-bond acceptor, exemplified by an ethanol moiety in the tryptamine derivative 3, was compatible with the activity and increased it. Furthermore, linking the triazine ring with pyrazolone and phenyl moieties, as seen in compound 15, resulted in increased antibacterial activity.83 Whereby, the diazabiphenyl derivative 14 exhibited considerable antibacterial activity, which is thought to arise from the ability of its nitrogen atoms to form stabilizing hydrogen bonds with target proteins-an interaction often essential for the bactericidal action.33

3 Experimental

3.1 General methodology for preparation of 6-acetyl-1,2,4-triazine derivatives

One-pot three component reaction of (phenylhydrazineylidene)propan-2-one 1 (0.53 g, 3.3 mmol) with formalin (0.54 ml, 6.6 mmol, 37%) and various amines (3.3 mmol) involving dodecylamine, tryptamine, 2-((diphenylboryl)oxy)ethanamine (5), 4-bromoaniline, 2-chloro-3-fluoroaniline, N-phenyl-p-phenylenediamine, 4-aminobenzophenone, 4-((4-nitrophenyl)diazenyl)aniline, benzidine and 4-aminoantipyrine in ethanol was refluxed on water bath as well as by ultrasound method for 120 min as optimized time to afford of functionalized nitrogenous molecules 2, 3, 6, 8, 9, 10, 11, 12, 14 and 15, respectively. Whereby, the synthesis of bis(2-phenylhydrazineylidene)heptane-2,6-dione 16 was achieved through repeating the same Mannich reaction methodology of synthesizing the compounds as above-mentioned in the presence of 2-aminobenzonitrile or 4H-1,2,4-triazol-3-amine or 1-amino-4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carbonitrile as nitrogenous systems.
3.1.1 1-(2-Phenylhydrazineylidene)propan-2-one (1). Yield = 55%; red powder; Lit. m.p.37 = 148–150 °C, m.p. = 142–144 °C; Rf = 0.78 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). 1HNMR (DMSO, d6); δ ppm 2.32 (s, CH3, 3H), 6.96 (t, J = 7.2 Hz, 1HAr), 7.18–7.20 (m, 2HAr), 7.25 (s, [double bond, length as m-dash]CH, 1H), 7.31–7.35 (m, 2HAr), 11.33 (s, NH, 1H). 13C NMR; δ ppm 24.60, 113.93 (2C), 122.11, 129.88 (2C), 135.14, 143.70, 196.84.
3.1.2 1-(4-Dodecyl-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one (2). Pale-yellow powder; m.p. = 56–58 °C; Rf = 0.67 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 2959, 2916, 2848 (sp3 C–H), 1726 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 0.86 (t, J = 6.6 Hz, 3H), 1.23 (m, 18H), 1.43–1.45 (m, 2H), 2.34 (s, CH3, 3H), 2.41 (t, J = 7.2 Hz, 2H), 3.49 (s, CH2 of –CCH2N–, 2H), 4.56 (s, CH2 of –NCH2N–, 2H), 7.03–7.07 (m, 1HAr), 7.35–7.41 (m, 4HAr). 13C NMR; δ ppm 14.44, 22.58, 23.83, 27.06, 27.30, 29.18, 29.26, 29.44, 29.48 (2C), 29.50, 31.77, 45.65, 53.33, 64.60, 115.19 (2C), 122.79, 129.72 (2C), 139.12, 145.24, 196.02. (EMIS) m/z (%): 371.14 (M+, 18.89%), 324.44 (57.86%), 203.02 (100%, base peak), 189.87 (65.15%), 185.00 (97.50%), 183.69 (56.24%), 175.22 (51.20%), 63.49 (48.98%). Anal. Calcd for C23H37N3O (371.57): C, 74.35, H 10.04, N 11.31%. Found C 74.32, H 10.06, N 11.27%.
3.1.3 1-(4-(2-(1-(Hydroxymethyl)-1H-indol-3-yl)ethyl)-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one (3). Yield = 63%; orange powder; m.p. = 182–184 °C; Rf = 0.17 EtOAc/petroleum ether (1[thin space (1/6-em)]:[thin space (1/6-em)]4). 1HNMR; δ ppm 1.25 (s, CH2, 2H), 2.44 (s, CH3, 3H), 2.72–2.79 (m, 4H), 3.66 (s, CH2, 2H), 3.88 (s, CH2, 2H), 6.93–7.04 (m, 3H), 7.19 (d, J = 7.6 Hz, 2H), 7.27–7.32 (m, 3H), 7.38 (d, J = 7.6 Hz, 1H), 10.75 (s, 1H), 11.61 (s, 1H, OH). 13C NMR; δ ppm 21.44, 24.51, 49.91, 50.34, 50.47, 79.58, 106.55, 111.43, 114.26 (2C), 117.90, 118.83, 120.95, 122.43, 127.00, 129.85 (2C), 132.37, 136.33, 139.03, 143.52, 196.40. (EMIS) m/z (%): 376.50 (M+, 20.70%), 367.40 (64.83%), 282.35 (28.81%), 275.35 (58.47%), 261.40 (31.84%), 233.11 (28.84%), 117.10 (100%, base peak), 89.23 (28.59%). Anal. Calcd for C22H24N4O2 (376.46): C 70.19, H 6.43, N 14.88%. Found C 70.23, H 6.46, N 14.85%.
3.1.4 1,1′-((Oxybis(ethane-2,1-diyl))bis(2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazine-4,6-diyl))bis(ethan-1-one) (6). Yield = 68%; pale-yellow powder; m.p. = 78–80 °C; Rf = 0.27 EtOAc/petroleum ether (1[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3043 (sp2 C–H), 2954, 2920, 2879 (sp3 C–H), 1646 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.35 (s, 2CH3, 6H), 2.54 (t, J = 5.8 Hz, 4H), 3.53–3.56 (m, 8H), 4.61–4.65 (m, 4H), 7.03–7.07 (m, 2HAr), 7.35–7.40 (m, 8HAr). 13C NMR; δ 23.84 (2C), 46.44 (2C), 55.96 (2C), 59.83 (2C), 65.11 (2C), 115.25 (4C), 122.80 (2C), 129.72 (4C), 139.29 (2C), 145.26 (2C), 196.01 (2C). 15NNMR; δ ppm −6.98 (2N), 199.98 (2N), and 406.95 (2N). (EMIS) m/z (%): 476.06 (M+, 13.27%), 264.01 (65.26%), 173.95 (35.98%), 167.64 (51.63%), 160.01 (55.15%), 129.95 (100%, base peak), 104.53 (48.37%), 90.51 (85.63%). Anal. Calcd for C26H32N6O3 (476.58): C, 65.53; H 6.77, N 17.63%. Found C 65.50, H 6.81, N 17.60%.
3.1.5 1-(4-(4-Bromophenyl)-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one (8). Off-white powder; m.p. = 116–118 °C; Rf = 0.80 EtOAc/petroleum ether (1[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3065, 3026, 3005 (sp2 C–H), 2896 (sp3 C–H), 1653 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.35 (s, CH3, 3H), 4.24 (s, NCH2C, 2H), 5.28 (s, NCH2N, 2H), 7.00 (d, J = 8.8 Hz, 2H), 7.09 (t, J = 7.2 Hz, 1H), 7.39–7.42 (m, 4HAr), 7.48 (d, J = 7.6 Hz, 2HAr). 13C NMR; δ ppm 23.96, 44.78, 61.40, 112.69, 115.29 (2C), 119.35 (2C), 123.19, 129. 84 (2C), 132.37 (2C), 139.45, 144.72, 147.88, 195.67. (EMIS) m/z (%): 358.41 (M+, 46.49%), 270.57 (100%, base peak), 220.57 (89.53%), 211.01 (73.44%), 209.48 (65.42%), 204.77 (61.24%), 196.62 (66.04%), 43.61 (61.29%). Anal. Calcd for C17H16BrN3O (358.24): C 57.00, H 4.50, N 11.73%. Found C 57.04, H 4.49, N 11.71%.
3.1.6 1-(4-(2-Chloro-3-fluorophenyl)-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one (9). Pale-yellow powder; m.p. = 138–140 °C; Rf = 0.60 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3061 (sp2 C–H), 2835 (sp3 C–H), 1654 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.36 (s, CH3, 3H), 4.23 (s, NCH2C, 2H), 5.26 (s, NCH2N, 2H), 7.01–7.11 (m, 2HAr), 7.28–7.32 (m, 2HAr), 7.41 (t, J = 7.8 Hz, 2HAr), 7.50 (d, J = 8 Hz, 2HAr). 19F-NMR; −δ 126.87 ppm. (EMIS) m/z (%): 331.54 (M+, 16.77%), 228.58 (89.42%), 215.18 (100%, base peak), 212.23 (68.87%), 169.11 (87.66%), 127.21 (77.75%), 81.26 (71.81%), 79.51 (81.06%). Anal. Calcd for C17H15ClFN3O (331.78): C 61.54, H 4.56, N 12.67%. Found C 61.52, H 4.59, N 12.63%.
3.1.7 1-(2-Phenyl-4-(4-(phenylamino)phenyl)-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one (10). Brown powder; m.p. = 170–172 °C; Rf = 0.45 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3353 (NH), 3023 (sp2 C–H), 2919 (sp3 C–H), 1659 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.36 (s, CH3, 3H), 4.18 (s, NCH2C, 2H), 5.20 (s, NCH2N, 2H), 6.73 (t, J = 7.4 Hz, 1HAr), 6.93–7.02 (m, 6HAr), 7.08 (t, J = 7.2 Hz, 1HAr), 7.16 (t, J = 7.8 Hz, 2HAr), 7.40 (t, J = 7.8 Hz, 2HAr), 7.48 (d, J = 8 Hz, 2HAr), 7.92 (s, NH, 1H, exchangeable with D2O). 13C NMR; δ ppm 23.90, 45.31, 62.59, 115.18 (2C), 115.82 (2C), 119.02 (2C), 119.11, 119.57 (2C), 123.04, 129.57 (2C), 129.84 (2C), 137.64, 139.60, 142.41, 144.79, 144.88, 195.76. (EMIS) m/z (%): 370.41 (M+, 30.99%), 367.48 (76.19%), 349.27 (93.95%), 347.23 (98.47%), 153.03 (69.31%), 91.41 (100%, base peak), 74.72 (66.44%), 68.29 (84.12%). Anal. Calcd for C23H22N4O (370.46): C 74.57, H 5.99, N 15.12%. Found C 74.53, H 6.01, N 15.15%.
3.1.8 1-(4-(4-Benzoylphenyl)-2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)ethan-1-one (11). Yellow powder; m.p. = 164–168 °C; Rf = 0.59 EtOAc/petroleum ether (1[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3061 (sp2 C–H), 2925, 2834 (sp3 C–H), 1723, 1669 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.39 (s, CH3, 3H), 4.39 (s, NCH2C, 2H), 5.41 (s, NCH2N, 2H), 7.11 (t, J = 7.2 Hz, 1HAr), 7.20 (d, J = 8.8 Hz, 2HAr), 7.43 (t, J = 7.8 Hz, 2HAr), 7.52–7.56 (m, 4HAr), 7.64–7.71 (m, 5HAr). 13C NMR; δ ppm 24.13, 44.34, 59.96, 115.42 (2C), 115.50 (2C), 123.32, 128.55, 128.89 (2C), 129.64 (2C), 129.89, 132.41 (4C), 138.38, 139.75, 144.65, 151.92, 194.55, 195.64. (EMIS) m/z (%): 383.27 (M+, 33.51%), 349.57 (92.21%), 342.06 (76.87%), 333.08 (63.22%), 325.85 (86.58%), 320.23 (100%, base peak), 164.03 (90.16%), 149.48 (69.41%). Anal. Calcd for C24H21N3O2 (383.45): C 75.18, H 5.52, N 10.96%. Found C 75.21, H 5.53, N 10.99%.
3.1.9 (1E)-N-(4-((E)-(4-Nitrophenyl)diazenyl)phenyl)-1-(2-phenylhydrazineylidene)propan-2-imine (12). Red powder; m.p. = 200–202 °C; Rf = 0.55 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3272 (NH), 3054 (sp2 C–H), 2925 (sp3 C–H), 1608, 1596, 1534 (C[double bond, length as m-dash]N & C[double bond, length as m-dash]C). 1HNMR; δ ppm 2.51 (s, CH3, 3H), 7.59–7.64 (m, 8H), 7.92 (d, J = 6.8 Hz, 2HAr), 8.02 (d, J = 8.4 Hz, 2HAr), 8.30 (d, J = 8.8 Hz, 2HAr), 13.33 (s, NH, 1H). (EMIS) m/z (%): 386.48 (M+, 10.15%), 291.72 (53.63%), 279.54 (56.97%), 242.15 (64.12%), 239.92 (100%, base peak), 223.94 (59.55%), 179.04 (58.15%), 103.42 (57.91%). Anal. Calcd for C21H18N6O2 (386.42): C 65.27, H 4.70, N 21.75%. Found C 65.31, H 4.67, N 21.77%.
3.1.10 1,1′-([1,1′-Biphenyl]-4,4′-diylbis(2-phenyl-2,3,4,5-tetrahydro-1,2,4-triazine-4,6-diyl))bis(ethan-1-one) (14). Buff powder; m.p. = 238–240 °C; Rf = 0.94 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3033 (sp2 C–H), 2924, 2853 (sp3 C–H), 1659, 1610 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.35 (s, 2CH3, 6H), 4.27 (s, 2NCH2C, 4H), 5.30 (s, 2NCH2N, 4H), 7.01–7.10 (m, 5HAr), 7.38–7.50 (m, 13HAr). 13C NMR; δ ppm 23.93 (2C), 44.89 (2C), 61.64 (2C), 115.19 (4C), 117.68 (4C), 123.10 (2C), 127.02 (2C), 127.32 (2C), 129.85 (4C), 132.61 (2C), 139.60 (2C), 144.75 (2C), 147.47 (2C), 195.72 (2C). (EMIS) m/z (%): 556.87 (M+, 32.96%), 287.95 (81.13%), 208.07 (100%, base peak), 201.56 (76.58%), 194.99 (79.44%), 96.76 (75.53%), 90.61 (94.20%), 41.43 (74.11%). Anal. Calcd for C34H32N6O2 (556.67): C 73.36, H 5.79, N 15.10%. Found C 73.33, H 5.81, N 15.13%.
3.1.11 4-(6-Acetyl-2-phenyl-2,5-dihydro-1,2,4-triazin-4(3H)-yl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (15). Yield = 86%; yellow powder; m.p. = 100–102 °C; Rf = 0.29 EtOAc/petroleum ether (1[thin space (1/6-em)]:[thin space (1/6-em)]4). IR (ν\/cm−1): 3063 (sp2 C–H), 2923, 2835 (sp3 C–H), 1650, 1629 (C[double bond, length as m-dash]O). 1HNMR; δ ppm 2.21 (s, CH3C[double bond, length as m-dash]O, 3H), 2.38 (s, CH3C–, 3H), 3.00 (s, CH3N–, 3H), 3.95 (s, NCH2C, 2H), 4.85 (s, NCH2N, 2H), 7.02–7.06 (m, 1HAr), 7.29–7.40 (m, 7HAr), 7.48 (t, J = 7.8 Hz, 2HAr). 13C NMR; δ ppm 10.67, 24.10, 36.57, 45.15, 62.88, 115.29 (2C), 117.65, 122.76, 123.81 (2C), 126.59 (1C), 129.48 (2C), 129.70 (2C), 135.40, 140.61, 144.76, 151.81, 162.56, 195.64. (EMIS) m/z (%): 389.09 (M+, 34.51%), 375.81 (76.32%), 330.70 (100%, base peak), 285.45 (79.14%), 253.70 (73.37%), 164.36 (70.75%), 69.47 (78.13%). Anal. Calcd for C22H23N5O2 (389.46): C 67.85, H 5.95, N 17.98%. Found C 67.89, H 5.91, N 18.01%.
3.1.12 (3Z,5E)-3,5-Bis(2-phenylhydrazineylidene)heptane-2,6-dione (16). Yield = 49–63%; orange powder; m.p. = 202–204 °C; Lit. m.p.46 = 204–205 °C; Rf = 0.80 EtOAc/petroleum ether (1.5[thin space (1/6-em)]:[thin space (1/6-em)]4). 1HNMR; δ ppm 2.45 (s, 2CH3, 6H), 3.75 (s, CH2, 2H), 7.03 (t, J = 7 Hz, 2HAr), 7.33–7.41 (m, 8HAr), 10.97 (s, 2H, 2NH). 13C NMR; δ ppm 19.82, 24.68 (2C), 114.52 (4C), 122.91 (2C), 129.99 (4C), 138.16 (2C), 143.46 (2C), 199.32 (2C).

3.2 In vitro antibacterial assay

Four bacterial strains (Bacillus subtilis, Staphylococcus epidermidis, and Enterobacter cloacae, and Escherichia coli) were implemented to assess the antibacterial efficacy of triazine derivatives. Azithromycin was adopted as a standard antibacterial agent for this evaluation, while DMSO was used as a negative control. The tested compounds exhibited promising antibacterial activity at a concentration of 20 mg with observable zones of inhibition.
3.2.1 Evaluation of minimal inhibitory concentration (MIC) for compounds 9 and 14. Serial dilutions of the sample in a concentration of 20 mg ml−1 for compounds 9 and 14 were used to determine MIC in the nutrient broth medium. The control contained only inoculated broth and was incubated for 24 h at 37 °C. The MIC endpoint is the lowest concentration of the sample where no visible growth is seen in the tubes. The visual turbidity of the tubes was noted, both before and after incubation to confirm the MIC value, and O.D was measured at 600 nm to confirm the result (Table 8).84
Table 8 Minimum inhibitory concentration (MIC) of compounds 9 and 14
Compound MIC (mg ml−1)
Strain B. subtilis S. epidermidis Entero. Cloacae E. coli
9 1.87 1.87 1.87 1.87
14 0.62 5 5 5


3.3 In silico molecular docking

Enzyme regulation studies were conducted using molecular docking to comprehend the observed differences in antibacterial activities among the synthesized compounds while considering the system's complexities. The three-dimensional structure of protein receptors was assessed from PDB (https://www.rcsb.org/) and prepared using Discovery Studio, whereas the ligands were constructed with Babel. Then receptors and ligands were subsequently uploaded into AutoDock Vina within PyMOL for docking analysis. Visualization of outcomes in both 2D and 3D formats was accomplished using Discovery Studio, providing a thorough understanding of the interaction dynamics between the ligands and their corresponding protein targets. Details about the bacteria's protein codes and resolutions are illustrated in Table 9.
Table 9 Lists the PDB's ID as well as their resolutions for the antibacterial
Bacteria Gram (+) Gram (−)
B. subtilis S. epidermidis Entero. Cloacae E. coli
PDB 1OF0 (ref. 64) 8P20 (ref. 67) 1KQB71,72 1KNZ74,75
Resolution 2.45 Å 2.85 Å 1.80 Å 2.45 Å


4 Conclusion

Concisely, this comprehensive study provides an eco-friendly, effective, and wide substrate approach for synthesizing bioactive, relevant triazine scaffolds via cascade double Mannich under mild green conditions. Also, we developed a prominent comparison of conventional versus ultrasound-assisted one-pot Mannich reactions for the divergent synthesis of functionalized 1,2,4-triazine building blocks, demonstrating that the ultrasound method yielded superior results in terms of both yield and time. The antibacterial activity of the tested compounds was further validated through in vitro and silico studies, indicating that scaffold 9 has a broad-spectrum against four bacterial types. Regarding tested triazine hybrids, the antibacterial efficacy against four bacterial species was lessened as follows: for Bacillus subtilis compound 9 > 10 > 14; for Staphylococcus epidermidis, 9 > 14 > 10; for Enterobacter cloacae, 9 > 14 > 10>; and Escherichia coli the order is 9 > 12 > 15 = 8. Whereas, in silico studies demonstrated responsible binding affinity with a binding energy of −7.905, −7.372, −6.880, and −7.544 kcal mol−1 for compound 9, sufficient to inhibit crucial 1OF0, 8P20, 1KQB, and 1KZN proteins, respectively. Finally, the optical activity of the synthesized compounds was measured to confirm the regioselective chirality of nitrogenous atoms at positions 2 and 4.

Data availability

All data and analysis during this study are available in this article and its ESI file.

Author contributions

H. A. A.: organic synthesis methodology, software, formal analysis, writing – original draft; M. M. H.: conceptualization, investigation, project administration, editing, validation; M. A. I.: conceptualization, supervision, investigation, project administration, editing, validation; E. A. G.: conceptualization, organic synthesis methodology, formal analysis, investigation, supervision, writing – original draft & editing, project administration; all authors reviewed the manuscript.

Conflicts of interest

The authors confirm that there are no known competing financial interests or personal relationships associated with this publication for this work that could have influenced its outcome.

Acknowledgements

The authors are indebted to Mansoura University for all the support and the facilities provided. This study is supported by funding from Prince Sattam bin Abdulaziz University's project number (PSAU/2024/R/1446).

References

  1. (a) N. Macesic, A.-C. Uhlemann and A. Y. Peleg, Lancet, 2025, 405, 257–272 CrossRef PubMed; (b) M. Naghavi, S. E. Vollset, K. S. Ikuta, L. R. Swetschinski, A. P. Gray, E. E. Wool, G. R. Aguilar, T. Mestrovic, G. Smith and C. Han, Lancet, 2024, 404, 1199–1226 CrossRef PubMed.
  2. A. Kumar, A. K. Singh, H. Singh, V. Vijayan, D. Kumar, J. Naik, S. Thareja, J. P. Yadav, P. Pathak and M. Grishina, Pharmaceuticals, 2023, 16, 299 CrossRef PubMed.
  3. M. B. Aktekin, Z. Oksuz, B. Turkmenoglu, E. S. Istifli, M. Kuzucu and O. Algul, Chem. Biol. Drug Des., 2024, 104, e14601 Search PubMed.
  4. S. Castañeda-Barba, E. M. Top and T. Stalder, Nat. Rev. Microbiol., 2023, 22, 18–32 Search PubMed.
  5. J. A. Alara and O. R. Alara, Infect. Disord.: Drug Targets, 2024, 24, 26–42 Search PubMed.
  6. S. A. Okaiyeto, P. P. Sutar, C. Chen, J.-B. Ni, J. Wang, A. S. Mujumdar, J.-S. Zhang, M.-Q. Xu, X.-M. Fang and C. Zhang, Agric. Commun., 2024, 2, 100027 Search PubMed.
  7. T. Sawa, K. Moriyama and M. Kinoshita, J. Intensive Care, 2024, 12, 44 CrossRef PubMed.
  8. J. Xuan, W. Feng, J. Wang, R. Wang, B. Zhang, L. Bo, Z.-S. Chen, H. Yang and L. Sun, Drug Resist. Updates, 2023, 68, 100954 CrossRef PubMed.
  9. N. Ahmad, S. N. A. Bukhari, M. A. Hussain, H. Ejaz, M. U. Munir and M. W. Amjad, RSC Adv., 2024, 14, 13535–13564 RSC.
  10. H. Sati, E. Carrara, A. Savoldi, P. Hansen, J. Garlasco and E. Campagnaro, WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, ed. World Health Organization, 2024, ISBN: 978-92-4-009346-1, https://www.who.int/publications/i/item/9789240093461 Search PubMed.
  11. M. S. Butler, W. Vollmer, E. C. A. Goodall, R. J. Capon, I. R. Henderson and M. A. T. Blaskovich, ACS Infect. Dis., 2024, 10, 3440–3474 CrossRef PubMed.
  12. R. H. Abd El-Aleam, R. F. George, H. H. Georgey and H. M. Abdel-Rahman, RSC Adv., 2021, 11, 36459–36482 RSC.
  13. J. Feng, Y. Zheng, W. Ma, D. Weng, D. Peng, Y. Xu, Z. Wang and X. Wang, Nat. Commun., 2024, 15, 6040 CrossRef PubMed.
  14. R. J. Melander and C. Melander, ACS Infect. Dis., 2017, 3, 559–563 CrossRef PubMed.
  15. (a) K. S. Kaye, A. S. Henriksen, M. Sommer and N. Frimodt-Møller, Clin. Infect. Dis., 2025, 80, 280–299 CrossRef CAS; (b) C. A. S. Valença, A. A. T. Barbosa, E. B. Souto, E. B. Caramão and S. Jain, Chem. Biodiversity, 2021, 18, e2100549 CrossRef PubMed.
  16. (a) L.-G. Ding, M. Shi, Y.-L. Xu, E.-D. Yu, Y.-Y. Zhang, J.-D. Li, F. Liu, B.-J. Yao, J. Yu and J.-Q. Wu, Adv. Funct. Mater., 2025, 2411237 CrossRef CAS; (b) S. Gupta and K. Paul, Eur. J. Med. Chem., 2023, 258, 115551 CrossRef CAS.
  17. (a) P. M. C. Matias, S. C. C. Nunes, A. C. B. Rodrigues, M. Ltayef, L. Sellaoui, M. Mbarek, D. Murtinho, A. A. C. C. Pais and A. J. M. Valente, Sep. Purif. Technol., 2025, 355, 129731 CrossRef CAS; (b) H. Liu, S. Long, K. P. Rakesh and G.-F. Zha, Eur. J. Med. Chem., 2020, 185, 111804 CrossRef CAS.
  18. S. K. De, Curr. Org. Synth., 2024, 21, 91–95 CrossRef CAS.
  19. G. H. Murhekar and S. D. Belsare, Mater. Today: Proc., 2023, 92, 1550–1562 Search PubMed.
  20. S. Cesarini, I. Vicenti, F. Poggialini, M. Secchi, F. Giammarino, I. Varasi, C. Lodola, M. Zazzi, E. Dreassi and G. Maga, Molecules, 2022, 27, 8829 CrossRef CAS PubMed.
  21. A. M. Ghanim, S. Rezq, T. S. Ibrahim, D. G. Romero and H. Kothayer, Eur. J. Med. Chem., 2021, 219, 113457 CrossRef CAS.
  22. R. Pal, B. Kumar, G. S. PM and P. A. Chawla, Bioorg. Chem., 2023, 131, 106284 CrossRef CAS PubMed.
  23. C. Pecoraro, M. De Franco, D. Carbone, D. Bassani, M. Pavan, S. Cascioferro, B. Parrino, G. Cirrincione, S. Dall'Acqua and S. Moro, Eur. J. Med. Chem., 2023, 249, 115134 CrossRef CAS PubMed.
  24. N. Shang, Y. Yang, Y. Xiao, Y. Wu, K. Li, X. Jiang, E. Sanganyado, Q. Zhang and X. Xia, Environ. Pollut., 2024, 342, 123069 CrossRef CAS.
  25. T. Yao, P. Sun and W. Zhao, Int. J. Mol. Sci., 2023, 24, 5691 CrossRef.
  26. P. Xiao, C. Li, Y. Liu, Y. Gao, X. Liang, C. Liu and W. Yang, Front. Pharmacol., 2024, 15, 1333543 CrossRef.
  27. T. Yoshikawa, Y. Kikko, R. Makino, Y. Kimijima, E. Nishiyama, Y. Matsuda, B. C. Teixeira, M. Tejada, R. Carroll and S. Hironaka, Gastric Cancer, 2024, 27, 827–839 CrossRef PubMed.
  28. Y. Geng, X. Bai, M. Huang, D. Kong, Y. Chen and Y. Gong, J. Mol. Struct., 2024, 1307, 138053 CrossRef.
  29. E. Vieta, S. Ghorpade, A. Biswas, A. Sarkar, A. Phansalkar and J. Cooper, Eur. Neuropsychopharmacol., 2024, 78, 81–92 Search PubMed.
  30. Q. Wang, Y. Suo, R. Shi and Y. Wang, Photodiagn. Photodyn. Ther., 2024, 49, 104287 CrossRef PubMed.
  31. A. Moanta, J. Chil. Chem. Soc., 2014, 59, 2275–2278 Search PubMed.
  32. H. A. Ali, M. A. Ismail, A. E.-A. S. Fouda and E. A. Ghaith, RSC Adv., 2023, 13, 18262–18305 RSC.
  33. X. Wang, H.-Y. Fu, W. He, Y.-T. Xiang, Z.-C. Yang, Y. Kuang and S.-X. Yang, Curr. Issues Mol. Biol., 2022, 44, 4087–4099 CrossRef PubMed.
  34. H. Katırcıoğlu, E. Loğoğlu, T. Tilki and A. Öktemer, Med. Chem. Res., 2007, 16, 205–212 CrossRef.
  35. Y. V Lykholat, N. O. Khromykh, O. O. Didur, T. V Sklyar, O. K. Balalaiev, M. M. Borova, V. M. Dzhagan and A. I. Yemets, Cytol. Genet., 2025, 59, 1–10 CrossRef.
  36. J. D. Georgiades, D. A. Berkovich, S. R. McKee, A. R. Smith, B. Sankaran, K. N. Flentie, C. H. Castañeda, D. G. Grohmann, R. Rohatgi and C. Lasky, ACS Infect. Dis., 2025, 11, 689–702 CrossRef PubMed.
  37. G. A. Reynolds and J. A. VanAllan, Org. Synth., 1963, 4, 633–634 Search PubMed.
  38. E. J. Slowik, K. Stankoska, N. N. Bui, B. Pasieka, D. Conrad, J. Zapp, M. Hoth, I. Bogeski and R. Kappl, Redox Biol., 2023, 61, 102654 CrossRef.
  39. T. Ishiguro, E. Kitamura, M. Matsumura and H. Ogawa, Pharm. Inst., 1955, 75, 1318–1321 CAS.
  40. F. A. Sherrod and B. R. Ezzell, US Pat., US4083873 A, No. 19, 1978 Search PubMed.
  41. T. F. Cummings and J. R. Shelton, J. Org. Chem., 1960, 25, 419–423 CrossRef CAS.
  42. W. L. Nobles and N. D. Potti, J. Pharm. Sci., 1968, 57, 1097–1103 CrossRef CAS PubMed.
  43. X. Lu, C. Huang, M. Li, D. Skomski, W. Xu, L. Yu, S. R. Byrn, A. C. Templeton and Y. Su, J. Phys. Chem. B, 2020, 124, 5271–5283 CrossRef CAS.
  44. T. Furuya, D. Benitez, E. Tkatchouk, A. E. Strom, P. Tang, W. A. Goddard and T. Ritter, J. Am. Chem. Soc., 2010, 132, 3793–3807 CrossRef CAS.
  45. M. Arend, B. Westermann and N. Risch, Angew. Chem., 1998, 110, 1096–1122 CrossRef.
  46. S. M. Al-Mousawi, M. S. Moustafa and M. H. Elnagdi, Heterocycles, 2008, 75, 2201–2211 CrossRef CAS.
  47. S. Majhi, Ultrason. Sonochem., 2021, 77, 105665 CrossRef CAS.
  48. K. Saini, Manju, A. K. Raigar, N. Jyoti and A. Guleria, ACS Omega, 2024, 9, 8343–8351 CrossRef CAS PubMed.
  49. M. Saquib, S. Ahamad, M. F. Khan, M. I. Khan and M. K. Hussain, Front. Pharmacol., 2023, 14, 1168566 CrossRef CAS.
  50. Z. Li, Y. Zheng, Q. Sun, J. Wang, B. Zheng and Z. Guo, Ultrason. Sonochem., 2021, 72, 105458 CrossRef CAS.
  51. B. Chen, S. Bao, Y. Zhang and L. Ren, J. Cleaner Prod., 2022, 339, 130755 CrossRef CAS.
  52. M. Wang, C. Li, M. Zhou, Z. Xia and Y. Huang, Green Chem., 2022, 24, 6696–6706 RSC.
  53. J. Lim, M. Guo, S. Choi, S. J. Miller and E. V. Anslyn, Chem. Sci., 2023, 14, 5992–5999 RSC.
  54. N. Senkuttuvan, B. Komarasamy, R. Krishnamoorthy, S. Sarkar, S. Dhanasekaran and P. Anaikutti, RSC Adv., 2024, 14, 33429–33448 RSC.
  55. G. Wang, A. Qu, M. Sun, J. Xu and H. Kuang, Acc. Mater. Res., 2024, 5, 1221–1236 CrossRef CAS.
  56. R. R. Steimbach, G. Tihanyi, M. N. E. Géraldy, A. Wzorek, A. K. Miller and K. D. Klika, Symmetry, 2021, 13, 1753 CrossRef CAS.
  57. L. Guo, Y. Guo, R. Wang, J. Feng, N. Shao, X. Zhou and Y. Zhou, Molecules, 2023, 28, 5629 CrossRef PubMed.
  58. B. Petrie and D. Camacho-Muñoz, Environ. Chem. Lett., 2021, 19, 43–75 CrossRef.
  59. L. Xu, L. Luo, H. Wu, Z. Luo, Z. Zhang, H. Shi, T. Chang, P. Wu, C. Du and H.-L. Cui, ACS Sens., 2020, 5, 2398–2407 CrossRef PubMed.
  60. J. Y. Lin, K. H. Chen and J. H. Chen, Appl. Opt., 2007, 46, 8134–8139 CrossRef PubMed.
  61. S. K. Talapatra and B. Talapatra, Chiroptical Properties I: Optical Rotation. ORD, CD, Basic Concepts in Organic Stereochemistry, 2023, pp. 211–228, ISBN: 978-3-030-95990-6 Search PubMed.
  62. S. S. ul Hassan and H. Jin, Front. Mar. Sci., 2025, 11, 1461607 CrossRef.
  63. S. G. Lakoud, N. Touil, H. Bouraoui, F. Hamoud, H. Harem, A. Ladjimi, M. Toffano, Y. Bedouh and A. Djahoudi, J. Mol. Struct., 2025, 1327, 141216 CrossRef.
  64. Y. Kanzouai, A. Bouribab, A. El Moussaoui, J. Touhtouh, M. Laghmari, R. Bouzammit, N. Aflak, K. Boujdi, S. Chtita and T. Benali, J. Mol. Struct., 2025, 1325, 140972 CrossRef.
  65. O. A. El-Gammal, A. A. El-Bindary, A. M. Eldesoky and I. M. Abd Al-Gader, J. Mol. Struct., 2025, 1322, 140339 CrossRef.
  66. F. J. Enguita, D. Marçal, L. O. Martins, R. Grenha, A. O Henriques, P. F Lindley and M. A. Carrondo, J. Biol. Chem., 2004, 279, 23472–23476 Search PubMed.
  67. Y. Guo, X. Du, J. Krusche, C. Beck, S. Ali, A. Walter, V. Winstel, C. Mayer, J. D. C. Codée and A. Peschel, Sci. Adv., 2023, 9, eadj2641 Search PubMed.
  68. P. Meshram, R. Dongre, M. Ahmed, S. Ahmed, R. Gajendhiran, A. KalilurRahiman, T. B. Hadda, K. M. Fahelelbom, A. R. Bhat and G. Tataringa, J. Mol. Struct., 2025, 1322, 140508 CrossRef.
  69. X.-M. Guo, C.-S. Liu, J.-P. Tong, Z.-L. Wang, X.-K. Feng, D.-D. Li, Y.-F. Wu and J. Sun, J. Mol. Struct., 2025, 1322, 140424 CrossRef.
  70. Y. Wang, J. Jiang, Y. Gao, Y. Sun, J. Dai, Y. Wu, D. Qu, G. Ma and X. Fang, J. Biol. Chem., 2018, 293, 14296–14311 CrossRef PubMed.
  71. C. A. Haynes, R. L. Koder, A.-F. Miller and D. W. Rodgers, J. Biol. Chem., 2002, 277, 11513–11520 CrossRef PubMed.
  72. S. Mirzaie, F. Rafii, K. Yasunaga, K. Yoshunaga, Z. Sepehrizadeh, S. Kanno, Y. Tonegawa and A. R. Shahverdi, Comput. Biol. Med., 2012, 42, 414–421 CrossRef CAS PubMed.
  73. C. A. Haynes, R. L. Koder, A.-F. Miller and D. W. Rodgers, J. Biol. Chem., 2002, 277, 11513–11520 CrossRef CAS PubMed.
  74. M. A. Ahemad, A. Patra, L. Muduli, S. Nayak, S. Mohapatra, J. Panda and C. R. Sahoo, Carbohydr. Res., 2024, 543, 109222 CrossRef CAS.
  75. R. Boudissa, A. Benmohammed, N. Chafai, A. Boudechicha, N. Rekiba, H. Lagraa, M. Achour, O. Khoumeri, A. Djafri and T. Terme, J. Mol. Struct., 2024, 1307, 138004 CrossRef CAS.
  76. A. Das, A. Das and B. K. Banik, J. Indian Chem. Soc., 2021, 98, 100005 CrossRef CAS.
  77. T. Kim, J. Zhen, J. Lee, R. Bauer, C. Lee, B.-O. Kwon, K. H. Chae, S. Hong, J. P. Giesy and G. S. Chang, Sci. Rep., 2020, 10, 13821 CrossRef CAS PubMed.
  78. D. Lafitte, V. Lamour, P. O. Tsvetkov, A. A. Makarov, M. Klich, P. Deprez, D. Moras, C. Briand and R. Gilli, Biochemistry, 2002, 41, 7217–7223 CrossRef CAS PubMed.
  79. Y. Zhou, Z. Sun, J. M. Froelich, T. Hermann and D. Wall, Bioorg. Med. Chem. Lett., 2006, 16, 5451–5456 CrossRef CAS PubMed.
  80. P. Singla, V. Luxami and K. Paul, Eur. J. Med. Chem., 2015, 102, 39–57 CrossRef CAS.
  81. D. Maliszewski, R. Demirel, A. Wróbel, M. Baradyn, A. Ratkiewicz and D. Drozdowska, Pharmaceuticals, 2023, 16, 1248 CrossRef.
  82. V. D. Cerón, L. A. Illicachi and B. Insuasty, Molecules, 2022, 28, 257 CrossRef.
  83. R. Bouley, D. Ding, Z. Peng, M. Bastian, E. Lastochkin, W. Song, M. A. Suckow, V. A. Schroeder, W. R. Wolter and S. Mobashery, J. Med. Chem., 2016, 59, 5011–5021 CrossRef PubMed.
  84. P. Parvekar, J. Palaskar, S. Metgud, R. Maria and S. Dutta, Biomater. Invest. Dent., 2020, 7, 105–109 Search PubMed.

Footnote

Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d5ra01283j

This journal is © The Royal Society of Chemistry 2025
Click here to see how this site uses Cookies. View our privacy policy here.